| Abstract: |
<p>Objective Datopotamab deruxtecan (Dato-DXd) is an antibody-drug conjugate comprised of a topoisomerase I inhibitor payload and a monoclonal antibody directed to trophoblast cell-surface antigen 2, a protein that is broadly expressed in several types of solid tumors. Dato-DXd demonstrated statistically significant improvement in median progression-free survival (mPFS) over docetaxel in patients with previously treated metastatic non-small cell lung cancer (mNSCLC) and over the investigator's choice of chemotherapy in patients with previously treated post-endocrine therapy hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer (mBC). Dato-DXd also demonstrated a distinct safety profile in both trials. The successful implementation of any new anticancer therapy requires learning how to prevent, monitor, and manage treatment-related adverse events (AE).Methods Perspectives were gathered from 4 medical oncologists, 2 nursing professionals, and 1 pharmacist with experience using Dato-DXd in either mNSCLC or mBC across several US practices.Results Here, we share practical insights and management and treatment of key AEs from Dato-DXd, including oral mucositis/stomatitis, nausea and vomiting, ocular surface events, and interstitial lung disease garnered from the multidisciplinary team of health care professionals experienced in treating patients with Dato-DXd.Conclusion Sharing experiences and institutional approaches from real-world clinical practices and multidisciplinary teams who treat patients with Dato-DXd may help provide a better patient experience and improved outcomes to a broader population of patients.</p> |
